Role of fibrates in reducing coronary risk: a UK Consensus

References

• Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998;81:912–7
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaeffer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–8
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo O, Frick H, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P et al. Lipid alterations and decline in the incidence of coronary heart disease – the Helsinki Heart Study. JAMA 1988;260(5):641–51
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;333:1001–9
   Google Scholar
• Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   Google Scholar
• MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80\(Suppl 2):S1–S29
   Google Scholar
• Expert panel in detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Sacks FM, for the Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol 2002;90:139–43
   Google Scholar
• Department of Health. National Service Framework for Coronary Heart Disease, London, 2000
   Google Scholar
• Sacks FM. Clinical usefulness of HDL cholesterol as a target to lower risk or coronary heart disease. Brit J Cardiol 2003;10(4):297–304
   Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539–53
   Google Scholar
• Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–9
   Google Scholar
• Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 1998;316: 823–8
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11–S20
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler A. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Rifkind BM. High-density lipoprotein – the clinical implications of recent studies. New Engl J Med 1989;321(19):1311–6
   PubMed Web of Science ®Google Scholar
• Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28(5):364–76
   Google Scholar
• Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893–1900
   Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   Google Scholar
• Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88(Suppl):14N–18N
   Google Scholar
• WHO co-operative study on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984:2:600–4
   Google Scholar
• The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21–7
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37–45
   PubMed Web of Science ®Google Scholar
• Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16(1):5–13
   PubMed Web of Science ®Google Scholar
• Shek A, Ferrill MJ. Statin–fibrate combination therapy. Ann Pharmacother 2001;35:908–17
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Statin–fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19(3):155–68
   PubMed Web of Science ®Google Scholar
• Vega GL, Ma PTS, Carter NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidaemia and metabolic syndrome. Am J Cardiol 2003;91: 956–60
   Google Scholar
• Telford M, Elisaf M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin 2003;19:139–40
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Clinical Practice Recommendations 2003. Diabetes Care 2003;26:S1–S156
   Google Scholar
• Management of type 2 Diabetes. Clinical Guideline H. National Institute of Clinical Excellence, London, 2002
   Google Scholar
• Tenkanen LJ, Manttari M, Manninen V. Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Evidence from the Helsinki Heart Study. Circulation 1995;92:1779–85
   PubMed Web of Science ®Google Scholar
• Poulter N. The impact of fenofibrate on lipid subfractions and on reaching HDL target levels in 7,098 patients with dyslipidaemia. Br J Cardiol 1999;6(12):682–5
   Google Scholar
• Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597–604
   Google Scholar
• Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325(7373):1139–44
   PubMed Web of Science ®Google Scholar